Published: May 19, 2025Updated: June 2, 2025Written by: Lukas Harnisch-WeidauerJyoti Bajpai, MD, DM, an oncologist practicing in the Apollo Hospital network in India, is well versed in treating rare cancers, but when she encountered someone with prostate cancer who was undergoing gender-affirming hormone replacement therapy, she found surprisingly little data to inform her approach. The … Read more
Boston residents rolled up their sleeps in anticipate of World Blood Donor Day on Saturday.
Published: May 7, 2025Written by: Dana-Farber Editorial TeamMedically Reviewed By: Ting Bao, MD, MSCold plunges, the act of immersing the body in cold water for…
When employees are satisfied in their work environment, the results speak for themselves. Newsweek and Plant-A Insights Group present America’s Greatest Workplaces 2025, recognizing companies…
In this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies…
Antibody-drug conjugates are targeted agents that package cancer drugs for special delivery to tumor cells to eliminate them.
At ASCO 2025, Dana-Farber Cancer Institute researchers are leading four studies with compelling and potentially practice changing results in colorectal cancer and breast cancer. Investigators…
A common gastrointestinal cancer drug that crosses the blood-brain barrier showed promise in patients with aggressive high-grade gliomas.
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program at Dana-Farber Cancer Institute is to provide resources and information to…
Learn the truth behind the myths about clinical trials. Understanding these can help patients make informed decisions about participation.
Bladder cancer treatment is advancing, two novel therapies have been recently approved for the treatment of non-muscle invasive bladder cancer. Learn more.
